9-Jan-2026
Catalyst Watch: Big bank earnings, major healthcare + retail conferences, Fedspeak flurry, CPI
Seeking Alpha News (Fri, 9-Jan 3:00 PM ET)
Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal
TipRanks (Fri, 9-Jan 1:23 AM ET)
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
Benzinga (Thu, 8-Jan 2:16 PM ET)
LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
TipRanks (Thu, 8-Jan 12:30 AM ET)
Novartis AG (NOVN) Gets a Hold from UBS
TipRanks (Wed, 7-Jan 11:36 AM ET)
JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
TipRanks (Wed, 7-Jan 10:46 AM ET)
Novartis AG (NOVN) was upgraded to a Hold Rating at Barclays
TipRanks (Wed, 7-Jan 4:25 AM ET)
Berenberg Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
TipRanks (Wed, 7-Jan 1:46 AM ET)
Berenberg Bank Sticks to Their Hold Rating for Novartis (NVS)
TipRanks (Wed, 7-Jan 1:46 AM ET)
J.P. Morgan Reaffirms Their Buy Rating on Novartis AG (NOVN)
TipRanks (Mon, 5-Jan 7:25 AM ET)
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of January 9, 2026, NVS stock price climbed to $141.54 with 1,044,335 million shares trading.
NVS has a beta of 0.31, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.07 to the broad based SPY ETF.
NVS has a market cap of $271.59 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $14 billion in Revenue and $2.25 earnings per share. This beat revenue expectation by $41 million and missed earnings estimates by -$.04.
In the last 3 years, NVS traded as high as $143.49 and as low as $79.98.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, PPH, DFIC, DFAI, AVDE.
NVS has outperformed the market in the last year with a price return of +45.1% while the SPY ETF gained +19.0%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.0% and +1.7%, respectively, while the SPY returned +3.7% and +0.5%, respectively.
NVS support price is $139.94 and resistance is $142.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.